Cargando…
First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection
Patient: Male, 72-year-old Final Diagnosis: SARS-CoV-2 Symptoms: Dyspnea Medication: Standard Clinical Procedure: C-reactive protein apheresis Specialty: Immunology OBJECTIVE: Unusual clinical course BACKGROUND: C-reactive protein (CRP) plasma levels in severe acute respiratory syndrome coronavirus...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377527/ https://www.ncbi.nlm.nih.gov/pubmed/32661220 http://dx.doi.org/10.12659/AJCR.925020 |
_version_ | 1783562234906017792 |
---|---|
author | Torzewski, Jan Heigl, Franz Zimmermann, Oliver Wagner, Florian Schumann, Christian Hettich, Reinhard Bock, Christopher Kayser, Stefan Sheriff, Ahmed |
author_facet | Torzewski, Jan Heigl, Franz Zimmermann, Oliver Wagner, Florian Schumann, Christian Hettich, Reinhard Bock, Christopher Kayser, Stefan Sheriff, Ahmed |
author_sort | Torzewski, Jan |
collection | PubMed |
description | Patient: Male, 72-year-old Final Diagnosis: SARS-CoV-2 Symptoms: Dyspnea Medication: Standard Clinical Procedure: C-reactive protein apheresis Specialty: Immunology OBJECTIVE: Unusual clinical course BACKGROUND: C-reactive protein (CRP) plasma levels in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel viral disease, are surprisingly high. Pulmonary inflammation with subsequent fibrosis in SARS-CoV-2 infection is strongly accelerated. Recently, we have developed CRP apheresis to selectively remove CRP from human plasma. CRP may contribute to organ failure and pulmonary fibrosis in SARS-CoV-2 infection by CRP-mediated complement and macrophage activation. CASE REPORT: A 72-year-old male patient at high risk was referred with dyspnea and fever. Polymerase chain reaction analysis of throat smear revealed SARS-CoV-2 infection. CRP levels were ∼200 mg/L. Two days after admission, CRP apheresis using the selective CRP adsorber (PentraSorb(®) CRP) was started. CRP apheresis was performed via peripheral venous access on days 2, 3, 4, and 5. Following a 2-day interruption, it was done via central venous access on days 7 and 8. Three days after admission the patient was transferred to the intensive care unit and intubated due to respiratory failure. Plasma CRP levels decreased by ∼50% with peripheral (processed blood plasma ≤6000 mL) and by ∼75% with central venous access (processed blood plasma ≤8000 mL), respectively. No apheresis-associated side effects were observed. After the 2-day interruption in apheresis, CRP levels rapidly re-increased (>400 mg/L) and the patient developed laboratory signs of multi-organ failure. When CRP apheresis was restarted, CRP levels and creatinine kinases (CK/CK-MB) declined again. Serum creatinine remained constant. Unfortunately, the patient died of respiratory failure on day 9 after admission. CONCLUSIONS: This is the first report on CRP apheresis in a SARS-CoV-2 patient. SARS-CoV-2 may cause multi-organ failure in part by inducing an excessive CRP-mediated autoimmune response of the ancient innate immune system. |
format | Online Article Text |
id | pubmed-7377527 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73775272020-08-05 First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection Torzewski, Jan Heigl, Franz Zimmermann, Oliver Wagner, Florian Schumann, Christian Hettich, Reinhard Bock, Christopher Kayser, Stefan Sheriff, Ahmed Am J Case Rep Articles Patient: Male, 72-year-old Final Diagnosis: SARS-CoV-2 Symptoms: Dyspnea Medication: Standard Clinical Procedure: C-reactive protein apheresis Specialty: Immunology OBJECTIVE: Unusual clinical course BACKGROUND: C-reactive protein (CRP) plasma levels in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel viral disease, are surprisingly high. Pulmonary inflammation with subsequent fibrosis in SARS-CoV-2 infection is strongly accelerated. Recently, we have developed CRP apheresis to selectively remove CRP from human plasma. CRP may contribute to organ failure and pulmonary fibrosis in SARS-CoV-2 infection by CRP-mediated complement and macrophage activation. CASE REPORT: A 72-year-old male patient at high risk was referred with dyspnea and fever. Polymerase chain reaction analysis of throat smear revealed SARS-CoV-2 infection. CRP levels were ∼200 mg/L. Two days after admission, CRP apheresis using the selective CRP adsorber (PentraSorb(®) CRP) was started. CRP apheresis was performed via peripheral venous access on days 2, 3, 4, and 5. Following a 2-day interruption, it was done via central venous access on days 7 and 8. Three days after admission the patient was transferred to the intensive care unit and intubated due to respiratory failure. Plasma CRP levels decreased by ∼50% with peripheral (processed blood plasma ≤6000 mL) and by ∼75% with central venous access (processed blood plasma ≤8000 mL), respectively. No apheresis-associated side effects were observed. After the 2-day interruption in apheresis, CRP levels rapidly re-increased (>400 mg/L) and the patient developed laboratory signs of multi-organ failure. When CRP apheresis was restarted, CRP levels and creatinine kinases (CK/CK-MB) declined again. Serum creatinine remained constant. Unfortunately, the patient died of respiratory failure on day 9 after admission. CONCLUSIONS: This is the first report on CRP apheresis in a SARS-CoV-2 patient. SARS-CoV-2 may cause multi-organ failure in part by inducing an excessive CRP-mediated autoimmune response of the ancient innate immune system. International Scientific Literature, Inc. 2020-07-14 /pmc/articles/PMC7377527/ /pubmed/32661220 http://dx.doi.org/10.12659/AJCR.925020 Text en © Am J Case Rep, 2020 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Articles Torzewski, Jan Heigl, Franz Zimmermann, Oliver Wagner, Florian Schumann, Christian Hettich, Reinhard Bock, Christopher Kayser, Stefan Sheriff, Ahmed First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection |
title | First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection |
title_full | First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection |
title_fullStr | First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection |
title_full_unstemmed | First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection |
title_short | First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection |
title_sort | first-in-man: case report of selective c-reactive protein apheresis in a patient with sars-cov-2 infection |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377527/ https://www.ncbi.nlm.nih.gov/pubmed/32661220 http://dx.doi.org/10.12659/AJCR.925020 |
work_keys_str_mv | AT torzewskijan firstinmancasereportofselectivecreactiveproteinapheresisinapatientwithsarscov2infection AT heiglfranz firstinmancasereportofselectivecreactiveproteinapheresisinapatientwithsarscov2infection AT zimmermannoliver firstinmancasereportofselectivecreactiveproteinapheresisinapatientwithsarscov2infection AT wagnerflorian firstinmancasereportofselectivecreactiveproteinapheresisinapatientwithsarscov2infection AT schumannchristian firstinmancasereportofselectivecreactiveproteinapheresisinapatientwithsarscov2infection AT hettichreinhard firstinmancasereportofselectivecreactiveproteinapheresisinapatientwithsarscov2infection AT bockchristopher firstinmancasereportofselectivecreactiveproteinapheresisinapatientwithsarscov2infection AT kayserstefan firstinmancasereportofselectivecreactiveproteinapheresisinapatientwithsarscov2infection AT sheriffahmed firstinmancasereportofselectivecreactiveproteinapheresisinapatientwithsarscov2infection |